About Natco Pharma Ltd.



Natco Pharma Limited is an Indian pharmaceutical company based in Hyderabad, Telangana, India. Established in 1981 as a private limited company, Natco Pharma develops, manufactures and markets finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company's major product categories include Domestic Formulations, International Formulations, APIs and Blockbusters.

As of 31st March 2016, Natco Pharma had:

  • 1 R&D facility in Sanath Nagar, Hyderabad
  • 9 globally certified manufacturing facilities across India


  • Contract manufacturing agreements with several pharmaceutical companies in India
  • A leading position in the Domestic Oncology segment
  • A portfolio of 13 products catering primarily to Gastroenterology, Orthopaedics and Critical Care/CNS


Natco Pharma Limited at-a-glance


  • Employees 3,500+
  • Net Revenue ~USD 174 million

(~?1152.38 crores)

  • Markets Served (countries) 40+
  • Manufacturing Facilities 9
  • ANDA Filings with USFDA 38

(as on 31 March 2016)

  • ANDAs Approved 19


*Source: http://www.natcopharma.co.in


  • WHO Compliant
  • Public Health Service of the Netherlands (EUGMP)
  • German Health Authority
  • PMDA Japan
  • COFEPRIS Mexico
  • ISO14001:2004 Compliant Environmental Management System
  • OHSAS-18001:2007




Please see Milestones below




  • 1981: Natco Pharma Division is incorporated at Kothur, District, Telangana

  • 1984: First year sales touch ?0.5 million

  • 1986: Inaugurates Parentals manufacturing facility at Nagarjuna Sagar , Telangana

  • 1993: Inaugurates Natco Chemical Division at Mekaguda, Telangana

  • 1995: Establishes Natco Trust and merges 3 groups companies with parent


  • 1997: Inaugurates Natco Research Center (NRC) at Sanathnagar, Hyderabad

  • 2003: Launches Oncology division with launch of flagship brand VEENAT for the

treatment of chronic myelogenous leukemia

  • 2006: Inaugurates world class finished dosage facility at Dehradun, Uttarakhand

  • 2007: Launches first ever ANDA in the US and acquires Save Mart Pharmacy in USA

  • 2008: Files first Paragraph IV in USA

  • 2009: Inaugurates NATCO Organics in Chennai for Cytotoxics, APIs & Biotechnology products, and achieves USD100 million turnover

  • 2011: Partners Levomed LLC, USA for sales and distribution in Brazil

  • 2012

  • Wins first ever compulsory license from Bayer for patent-protected

anti-cancer drug

  • Wins Golden Peacock Award for CSR

  • Establishes Natco Pharma Asia for sales and distribution in Singapore

  • 2013: Establishes Natco Pharma Canada for sales and distribution in Canada

  • 2014: Establishes Natco Pharma Australia for sales and distribution in Australia

  • 2015

  • Wins Golden Peacock Innovation Management Award

  • Launches generic Sovaldi in India and Nepal

  • 2016

  • Wins Golden Peacock Environment Management Award

  • Sells US based Save Mart Pharmacy store

  • 2017:

    • Launches new division for Cardiology and Diabetology (India market)

    • Launches first generic version of Sofosbuvir / Velpatasvir under its

brand Velpanat in Nepal




  • Chairman Mr V.C Nannapaneni
  • Vice Chairman & CEO Mr Rajeev Nannapaneni
  • President - R&D & Technical Dr AKS Bhujanga Rao
  • President - Technical Affairs Dr Donthineni Linga Rao
  • Director - Formulations Dr. B Rami Reddy
  • CFO Mr SVVN Appa Rao



Natco Pharma Limited

Natco House

Road #2, Banjara Hills

Hyderabad-500 034

Telangana, India

Website: www.natcopharma.com

Tel: +91-40-2354 7532

+91-40-2354 5298/23548243

Email: natinfo@natcopharma.co.in





* Indicates mandatory field.
Please wait while comments are being sent...